Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression

Xin Jin, Donglin Ding, Yuqian Yan, Hui Li, Bo Wang, Linlin Ma, Zhenqing Ye, Tao Ma, Qiang Wu, Daniel N. Rodrigues, Manish Kohli, Rafael Jimenez, Liguo Wang, David W. Goodrich, Johann de Bono, Haidong Dong, Heshui Wu, Runzhi Zhu, Haojie Huang

Research output: Contribution to journalArticle

29 Scopus citations

Abstract

RB is known to act as a tumor suppressor by inhibiting E2F transcription factors, and this function is abolished due to its phosphorylation by CDKs. Jin et al. identify a previously uncharacterized tumor suppressor role of CDK4/6-phosphorylated RB in promoting cancer immunity via inhibition of NF-κB transcriptional activity and PD-L1 expression.

Original languageEnglish (US)
Pages (from-to)22-35.e6
JournalMolecular Cell
Volume73
Issue number1
DOIs
StatePublished - Jan 3 2019

Keywords

  • CDK4/6 inhibitor
  • CHD1
  • MAP3K7
  • NF-κB
  • PD-L1
  • RB
  • immunotherapy
  • phosphorylation
  • prostate cancer
  • radiotherapy

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Fingerprint Dive into the research topics of 'Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression'. Together they form a unique fingerprint.

  • Cite this

    Jin, X., Ding, D., Yan, Y., Li, H., Wang, B., Ma, L., Ye, Z., Ma, T., Wu, Q., Rodrigues, D. N., Kohli, M., Jimenez, R., Wang, L., Goodrich, D. W., de Bono, J., Dong, H., Wu, H., Zhu, R., & Huang, H. (2019). Phosphorylated RB Promotes Cancer Immunity by Inhibiting NF-κB Activation and PD-L1 Expression. Molecular Cell, 73(1), 22-35.e6. https://doi.org/10.1016/j.molcel.2018.10.034